Areas of Interest
Sanofi is seeking the following type of opportunities in the therapeutic areas provided below:

• Early stage compounds, small molecules or biologics targeting novel disease mechanisms
• Disease relevant targets with validated mechanism of action
• Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
• Novel therapeutic modalities

IMMUNOLOGY & INFLAMMATION
• Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
• Type 1/17 immune responses and Rheumatological disorders including Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, and IBD
• Autoimmune sequelae of checkpoint inhibition
• Co-stimulation and co-inhibitory pathways in autoimmune and allergic diseases
• Immune tolerance, organ-specific autoimmunity and emerging immunotherapies for autoimmune disease.
• Systems and computational immunology
• Immuno-metabolism

IMMUNO-ONCOLOGY
• Mechanisms of innate and acquired resistance to checkpoint blockade
• Immuno-modulatory function of CD38
• Immuno-modulatory function of TGFb
• Immune cell engagers (NK cells & T cells engagers)
• Immuno-conjugates
• Novel ADC targets
• Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
• Immune profiling methodologies in preclinical and clinical setting
• Novel translational models in IO

MOLECULAR ONCOLOGY
Sanofi priority indications are breast, lung, multiple myeloma, prostate but also could be other cancers pending on target or modality

• Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
• Tumor induced immune-suppression: regulation of anti-tumor immunity when the target is located in tumor cells
• Tumors microenvironment targeting programs
• Modality: targeted protein degradation (PROTAC, Glue, monovalent degrader)

Sanofi iAwards: Call-for-Proposals
Each selected iAward project will receive:

• $125,000 research funding (including institutional indirect costs) for 12 months
• Sanofi scientific expertise, dedicated project management support and a scientific champion
• In-kind resources such as reagents, tool compounds, etc., if deemed necessary to advance the project
• Successful projects could be converted to SRAs and receive additional funding for 2-3 years

The deadline for submission is June 3rd, 2020